Fundraising Fox
/Companies
Sign in

Alamar Biosciences

Fremont, US · Founded 2018 · 243 employees on LinkedIn · 3 known investors

Find your way into Alamar Biosciences

Each arrow is one introduction. Sign up to fill in the first one.

352 people can intro you to Anna

Ask Peter Moran to introduce you to Anna Berdine

You →Peter · together at Alamar Biosciences →Anna

306 people can intro you to Steve

Ask Jamie Chen to introduce you to Steve Williams

You →Jamie · together at SomaLogic →Steve

185 people can intro you to Alex

Ask Sam Okafor to introduce you to Alex Forrest-Hay

You →Sam · together at Seer →Alex

Sign up to find every way you can get introduced to Alamar Biosciences

  • Your email: who you already know at Alamar Biosciences, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Alamar Biosciences team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope). The company serves proteomics research and clinical drug development applications.

BiotechDeep TechHealthtech

Founders & leadership

Alamar Biosciences was founded in 2018 by Yuling Luo, Steve Chen, and Yiyuan Yin.

YLYuling Luo
Yuling LuoCo-founder, CEO and ChairInvestor at Unknown Investment Firm
SCSteve Chen
Steve ChenCo-founder, COO and DirectorCo-founder, COO and Director at Alamarbio
YYYiyuan Yin
Yiyuan YinCo-founder, VP of TechnologyCo-founder, VP of Technology at Alamarbio
TWTod White
Tod WhitePresidentHe previously worked as a transactional attorney at an AmLaw 200 firm, served as General Counsel at a multinational life sciences company, and founded a boutique investment banking firm.
JMJustin McAnear
Justin McAnearCFOCFO at Alamarbio
XMXiao-Jun Ma
Xiao-Jun MaCTO
SWSteve Williams
Steve WilliamsCSOHe has held leadership roles in biomarker development, translational medicine, and diagnostics across pharma, biotech, and clinical settings, including establishing biomarker programs and clinical assay operations, and has contributed to FDA guidance on biomarker qualification and co-founded the Biomarkers Consortium with FDA and FNIH.
ABAnna Berdine
Anna BerdineSVP, MarketingAnna Berdine is SVP of Marketing at Alamar Biosciences, which develops NULISA, an ultra-high-sensitivity protein biomarker analysis technology for proteomics research and clinical drug development. She brings over 20 years of biotech experience in strategy, product management, marketing, and commercialization for both capital equipment and consumable businesses.
AFAlex Forrest-Hay
Alex Forrest-HaySVP of SalesAlex Forrest-Hay brings 26 years of sales experience across academic, government, healthcare, pharmaceutical, and commercial sectors, with 10 years in European markets and 16 years in North America leading global teams in life sciences, and holds expertise in genomics, transcriptomics, immuno-oncology, pathology, proteomics, and metabolomics. He serves as SVP of Sales at Alamar Biosciences, which develops the NULISA platform for high-sensitivity protein biomarker analysis from small biofluid samples.
MLMicah Litow
Micah LitowSVP, AI & Strategic InitiativesSVP, AI & Strategic Initiatives at Alamarbio

Investors · 3

Qiming Venture Partnerslisted by Qiming Venture PartnersBeijing

How we know: Qiming Venture Partners's portfolio page · the VCSheet dataset · Not right? Tell us

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · Not right? Tell us

Related companies · 2

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
QuanterixQuanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention. The company serves the precision healthcare and life sciences research market with biomarker detection tools.

Companies working in the same space as Alamar Biosciences.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$321.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Alamar Biosciences do?
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope). The company serves proteomics research and clinical drug development applications.
Who founded Alamar Biosciences?
Alamar Biosciences was founded by Yuling Luo, Steve Chen, Yiyuan Yin in 2018.
Who are Alamar Biosciences's investors?
Alamar Biosciences's investors include Illumina Ventures, Qiming Venture Partners, Samsara BioCapital.
Where is Alamar Biosciences headquartered?
Alamar Biosciences is headquartered in Fremont, US.